MX2009003794A - Composicion de prostaglandina e estabilizada. - Google Patents

Composicion de prostaglandina e estabilizada.

Info

Publication number
MX2009003794A
MX2009003794A MX2009003794A MX2009003794A MX2009003794A MX 2009003794 A MX2009003794 A MX 2009003794A MX 2009003794 A MX2009003794 A MX 2009003794A MX 2009003794 A MX2009003794 A MX 2009003794A MX 2009003794 A MX2009003794 A MX 2009003794A
Authority
MX
Mexico
Prior art keywords
prostaglandin
composition
alkyl
carboxylic ester
alcohols
Prior art date
Application number
MX2009003794A
Other languages
English (en)
Inventor
Daniel W Frank
Yiping Wang
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of MX2009003794A publication Critical patent/MX2009003794A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición de prostaglandina E sustancialmente libre de alcoholes (C1-C4) e incluye el compuesto de prostaglandina E junto con un éster carboxílico (C1-C4)-alquilo (C8-C22) (por ejemplo, laurato de etilo), un alquilamino N,N-di(C1-C9) sustituido, éster carboxílico (C4-C18) alquilo (C2-C18) y/o una sal de adición farmacéuticamente aceptable de las mismas y, de manera opcional, un agente que intensifica la viscosidad tal como goma guar. La composición de la prostaglandina E puede ser combinada con un diluyente alcohólico acuoso para formar una composición farmacéutica para aplicación tópica a un paciente, por ejemplo, para tratar disfunción sexual. Las composiciones de prostaglandina E son estables durante periodos prolongados de almacenamiento a temperatura ambiente.
MX2009003794A 2006-10-11 2007-10-05 Composicion de prostaglandina e estabilizada. MX2009003794A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/546,196 US7560489B2 (en) 2006-10-11 2006-10-11 Stabilized prostaglandin E composition
PCT/US2007/021374 WO2008045309A1 (en) 2006-10-11 2007-10-05 Stabilized prostaglandin e composition

Publications (1)

Publication Number Publication Date
MX2009003794A true MX2009003794A (es) 2009-04-24

Family

ID=39283156

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009003794A MX2009003794A (es) 2006-10-11 2007-10-05 Composicion de prostaglandina e estabilizada.

Country Status (12)

Country Link
US (1) US7560489B2 (es)
EP (1) EP2073634A4 (es)
JP (1) JP5382800B2 (es)
KR (1) KR101400359B1 (es)
AU (1) AU2007307136B2 (es)
BR (1) BRPI0719228A2 (es)
CA (1) CA2665611C (es)
IL (1) IL197885A (es)
MX (1) MX2009003794A (es)
NZ (1) NZ576242A (es)
WO (1) WO2008045309A1 (es)
ZA (1) ZA200902467B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
NZ592300A (en) 2008-10-03 2013-01-25 Nexmed Holdings Inc Stabilized composition for treating psoriasis
ES2921527T3 (es) 2009-06-03 2022-08-29 Forsight Vision5 Inc Administración de fármaco en segmento anterior
RU2012153177A (ru) 2010-05-04 2014-06-20 Нексмед Холдингс, Инк. Композиции низкомолекулярных терапевтических средств
CA2797966A1 (en) * 2010-05-04 2011-11-10 Nexmed Holdings, Inc. Therapeutic peptide composition and method
CA2745320A1 (en) 2011-07-06 2013-01-06 Duoject Medical Systems Inc. Reconstitution device
RU2740680C2 (ru) 2011-09-14 2021-01-19 Форсайт Вижн5, Инк. Глазное вкладочное устройство и способы
CN104884006B (zh) 2012-10-26 2017-12-15 弗赛特影像5股份有限公司 用于持续释放药物到眼睛的眼科***
WO2016168141A1 (en) 2015-04-13 2016-10-20 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036954A (en) * 1973-11-02 1977-07-19 Yamanouchi Pharmaceutical Co., Ltd. Stable prostaglandin E group-containing formulation
US4113882A (en) * 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
JPS5770816A (en) * 1980-10-17 1982-05-01 Ono Pharmaceut Co Ltd Multilayered film preparation of prostagladin of prolonged action
JPS58134019A (ja) * 1982-02-05 1983-08-10 Ono Pharmaceut Co Ltd プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
US4806354A (en) * 1984-04-06 1989-02-21 Green James P Health food composition
US5525348A (en) * 1989-11-02 1996-06-11 Sts Biopolymers, Inc. Coating compositions comprising pharmaceutical agents
CA2071137A1 (en) * 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
US6046244A (en) * 1997-11-05 2000-04-04 Nexmed Holdings, Inc. Topical compositions for prostaglandin E1 delivery
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6825234B2 (en) * 1998-12-10 2004-11-30 Nexmed (Holdings) , Inc. Compositions and methods for amelioration of human female sexual dysfunction
US6693135B2 (en) * 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20040110843A1 (en) * 2000-01-10 2004-06-10 Nexmed (Holdings), Inc. Methods of treatment of male erectile dysfunction
GB2372213B (en) * 2000-11-17 2003-07-16 Icebella Enterpises Ltd Applicator and stimulator device
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
EP1462098B1 (en) * 2003-03-03 2007-07-04 SPRL Franpharma Stabilised pharmaceutical composition comprising a non-steroidal anti-inflammatory agent and a prostaglandin
AR043476A1 (es) * 2004-09-09 2005-08-03 Dvoskin Victor Oscar Dispositivo de administracion regulada de sustancias para la insercion en una cavidad corporal y procedimiento para fabricar un medio de soporte de dichas sustancias
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition

Also Published As

Publication number Publication date
ZA200902467B (en) 2010-03-31
BRPI0719228A2 (pt) 2015-02-03
WO2008045309A1 (en) 2008-04-17
KR101400359B1 (ko) 2014-06-19
IL197885A (en) 2016-04-21
JP5382800B2 (ja) 2014-01-08
CA2665611A1 (en) 2008-04-17
US20080090911A1 (en) 2008-04-17
US7560489B2 (en) 2009-07-14
AU2007307136B2 (en) 2013-12-05
EP2073634A4 (en) 2012-12-19
AU2007307136A1 (en) 2008-04-17
NZ576242A (en) 2012-04-27
KR20090064597A (ko) 2009-06-19
EP2073634A1 (en) 2009-07-01
JP2010506831A (ja) 2010-03-04
IL197885A0 (en) 2009-12-24
CA2665611C (en) 2014-11-25

Similar Documents

Publication Publication Date Title
MX2009003794A (es) Composicion de prostaglandina e estabilizada.
CA2757418C (en) Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
MX2011010415A (es) Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas.
BR112012018384A2 (pt) composição farmacêutica sólida com intensificadores e métodos de preparação da mesma.
MA33768B1 (fr) Triazolopyridines
WO2008030744A3 (en) Inhibitors of c-met and uses thereof
IN2014CN02592A (es)
UA94606C2 (ru) Производные тиоксантина, композиция, которая их содержит, и их применение в терапии
MX2011012628A (es) Derivados amino-propionicos sustituidos como inhibidores de neprilisina.
WO2007145991A3 (en) Anti-inflammatory and analgesic compositions and related methods
WO2007137066A3 (en) HETEROCYCLIC INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME
WO2012071389A3 (en) Stable cannabinoid compositions and methods for making and storing them
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
PE20130236A1 (es) Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo
NZ714558A (en) Formulation comprising a hypolipidemic agent
MX2020008173A (es) Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos.
RU2011138962A (ru) Производные 4-изопропилфенилглюцита в качестве ингибиторов sglt1
UA109421C2 (uk) Фармацевтична композиція, яка містить ліганди сигма-рецептора
MY155938A (en) Oral pharmaceutical composition
TN2013000257A1 (en) Immunosuppressant formulations
BR112013030939A2 (pt) derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo
WO2009007137A3 (en) Pharmaceutical composition for topical application of poorly soluble compounds
NZ603108A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
PH12015500864A1 (en) Liquid formulation comprising gm-csf neutralizing compound

Legal Events

Date Code Title Description
FG Grant or registration